Based on IHC expression of immune co-inhibitory molecules in our cohort, tumor cells of SCLC were found to be poor immuno-expresser of PD-L1 and IDO1, while CTLA-4 immunolabelling was seen in a fair number of cases. This evidence concerns the gene CTLA4 and neoplasm.